Most-favored-nation pricing is “founded on incorrect assumptions about where high out-of-pocket costs really come from and what it would mean for the US to adopt cost-effectiveness standards used by ...

Rigorous answers about the program’s effects on drug innovation are still a ways off. However, some information about ...

Trump's executive order on drug prices gives no information on actual price targets and it doesn't disclose a plan for how to ...

The Health Resources and Services Administration has overseen the 340B Drug Pricing Program since its creation in 1992. That ...

President Trump’s executive order aims to bring down drug prices while optimizing IP protections, and Congress should pass ...

President Trumps May 12 executive order on drug pricing seeks to implement most-favored-nation (MFN) pricing, pressuring ...

Signed on May 12, the order aims to enforce most-favored-nation (MFN) pricing by directing the Secretary of Health and Human ...

A new State of Drug Access report shows that more than 40% of people living in the US could not afford their prescribed drugs ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy.

President Donald Trump issued an executive order (EO) on May 12, 2025 to address the high cost of prescription drugs in the ...